更新形淋巴瘤激酶阳性非小细胞肺癌治疗的进展

Beatriz E Jimenez Munarriz1, Sam Khan1,2, Yuchen Li1,3,4

  • 1Medical Oncology Department, University Health Network-Princess Margaret Cancer Center, Toronto, Ontario, Canada.

Cancer
|April 2, 2025
PubMed
概括

无细胞淋巴瘤激酶 (ALK) 的重组影响了晚期非小细胞肺癌 (NSCLC) 的治疗. ALK氨酸激酶抑制剂 (TKIs) 改善了结果,本次审查涵盖了当前的选择,疗效和未来的方向.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K